Loading
A phase 1/2 trial of Pembrolizumab, Fluorouracil (5-FU), Oxaliplatin and Sacituzumab tirumotecan in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) is a phase 1/2 interventional study registered as NCT06780111 by Merck Sharp & Dohme LLC, with 298 participants planned, started 2025-07-30 and due to reach its primary completion in 2032-01-04. Interventions recorded: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) and Oxaliplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, Oxaliplatin, Fluorouracil (5-FU), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer, Pembrolizumab and the tag pipeline.
Shares Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Daiichi Sankyo, Merck & Co. (MSD), Oesophageal cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Fluorouracil (5-FU), Oesophageal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/